PCM
TPTX

Pinz Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Pinz Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-700
Closed -$45K – 201
2020
Q2 		$45K Buy
+700
New +$40.4K 0.02% 109

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Pinz Capital Management's TPTX Position: Q3 2020 in Review

Pinz Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2020, closing a stake of 700 shares — an estimated $45K sold.

Pinz Capital Management first reported a position in TPTX in Q2 2020 and held it in 1 quarter. The position peaked at $45K in Q2 2020. 166 funds tracked by Wall St. Rank hold TPTX as of Q3 2020.

  • Pinz Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Pinz Capital Management sold 700 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $45K.
  • Pinz Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Pinz Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $45K in Q2 2020.
  • 166 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Pinz Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.